👉👉 🇺🇸 All Posts 🇬🇧 / 🇯🇵 記事一覧 🇯🇵 👈👈
♦️ Introduction
Your next patient has cirrhosis and needs urgent surgery. Which anesthetic agents can you safely use?
In patients with liver dysfunction, impaired metabolism alters drug clearance, leading to delayed emergence, oversedation, or even increased bleeding risk.
This article reviews modern anesthetic choices—including Remimazolam and Rocuronium—for patients with hepatic impairment.
💉 Safe and Unsafe Anesthetic Agents
The liver metabolizes most anesthetic drugs. When hepatic function is reduced, both clearance and pharmacodynamics change significantly.
✅ Recommended agents:
- Remifentanil: Metabolized by plasma esterases, not the liver. Clearance remains intact even in severe hepatic failure. Use standard doses, but be aware of increased respiratory sensitivity.
- Sevoflurane and Desflurane: Minimal hepatic metabolism and rapid recovery make them the preferred volatile agents in liver disease.
- Propofol: Undergoes partial extrahepatic metabolism (lungs, kidneys). Safe in most cases, but reduce the dose by 25–50% in severe liver dysfunction to avoid prolonged sedation.
- Remimazolam: Metabolized mainly by hepatic carboxylesterases. Pharmacokinetics are largely unchanged in mild to moderate liver impairment, but clearance may drop by ~40% in Child-Pugh C, leading to prolonged effect. Use lower infusion rates and monitor depth with BIS when possible.
💪 Neuromuscular Blockers: Rocuronium vs. Vecuronium
Both are aminosteroid non-depolarizing agents, but their handling in liver disease differs substantially.
| Feature | Rocuronium | Vecuronium |
|---|---|---|
| Main elimination | Biliary (80–90%) | Hepatic metabolism + biliary & renal excretion |
| Onset | Rapid (1–2 min) | Slower (3–5 min) |
| Duration in liver disease | Prolonged, but predictable | Markedly prolonged and cumulative |
| Active metabolites | None | Yes – 3-desacetyl vecuronium (active metabolite) |
| Reversal | Rapid and reliable with Sugammadex | Reversible but slower with Sugammadex |
| Availability | Widely used in Japan | ❌ Discontinued in Japan (since 2023); still available in some countries |
| Clinical impression | Safe with monitoring; easily reversed | Higher risk of accumulation; avoid in liver failure |
💡 Summary:
- Vecuronium is more prone to accumulation due to active metabolites and hepatic metabolism, making it unsuitable for patients with liver impairment.
- In Japan, Vecuronium has been completely discontinued, while Rocuronium remains standard practice.
- With Sugammadex, Rocuronium can be safely and promptly reversed, even if its duration is prolonged in cirrhosis.
⚖️ Dosing and Recovery
For moderate to severe liver dysfunction, reduce the dosage of hepatically metabolized drugs by 25–50%.
Expect slower recovery and prolonged effects with agents such as Propofol, Remimazolam, and Rocuronium.
Use BIS and TOF monitoring for real-time titration and safe extubation planning.
🔹 Note: Bleeding Risk and Regional Anesthesia
In liver failure, reduced synthesis of coagulation factors increases the risk of bleeding. Checking PT-INR, platelet count, and fibrinogen is essential before any procedure.
⚠️ In cases of severe thrombocytopenia or coagulopathy, epidural anesthesia, spinal (subarachnoid) anesthesia, and certain regional nerve blocks should be avoided.
💡 Take-Home Points
- Remifentanil, Sevoflurane, Desflurane, Propofol, and Remimazolam are generally safe choices.
- Rocuronium can be used with monitoring; Sugammadex enables rapid reversal.
- Vecuronium carries a high risk of accumulation and is no longer available in Japan (though still used in some countries).
- Halothane is contraindicated.
- Reduce hepatically metabolized drugs (e.g., Fentanyl, Midazolam) by 25–50%.
- Avoid regional anesthesia if coagulation is impaired.